The company is scaling its study from 50 to 135 participants to better evaluate the drug's efficacy across the full spectrum of disease severity. By utilizing the Eczema Area and Severity Index, researchers aim to gather robust data that could eventually support broader clinical development and future labeling opportunities.
In section Market Quotes
Turn Therapeutics Expands GX-03 Eczema Trial After Strong Early Results
Shares of Turn Therapeutics climbed 9.7% to $10.01 on Monday morning following the company's decision to significantly enlarge its Phase 2 clinical trial for the atopic dermatitis treatment GX-03. The stock has surged roughly 194% over the past three months as investors react to the drug’s potential.
Chief Executive Bradley Burnam noted that the adaptive trial design allows the company to refine its approach based on early signals. GX-03 has shown meaningful activity in patients beyond the initial severity projections. Enrollment remained active throughout the review period, with no serious treatment-related adverse events reported. The company expects to finalize patient recruitment for the study by the fourth quarter of 2026.
Comments (0)
No comments yet. Be the first!